Loading...
Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions
Ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody, was the first therapy demonstrated to improve overall survival in melanoma. Since ipilimumab’s approval by the FDA in 2011, a wealth of data have amassed, helping clinicians to optimize its use. We have learned how to mitigate the advers...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3799873/ https://ncbi.nlm.nih.gov/pubmed/23933888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11912-013-0337-1 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|